Journal article
Mesenchymal stem cell therapy: Two steps forward, one step back
Trends in molecular medicine, Vol.16(5), pp.203-209
05/2010
DOI: 10.1016/j.molmed.2010.02.005
PMCID: PMC2881950
PMID: 20335067
Abstract
Mesenchymal stem cell (MSC) therapy is poised to establish a new clinical paradigm; however, recent trials have produced mixed results. Although MSC were originally considered to treat connective tissue defects, preclinical studies revealed potent immunomodulatory properties that prompted the use of MSC to treat numerous inflammatory conditions. Unfortunately, although clinical trials have met safety endpoints, efficacy has not been demonstrated. We believe the challenge to demonstrate efficacy can be attributed in part to an incomplete understanding of the fate of MSC following infusion. Here, we highlight the clinical status of MSC therapy and discuss the importance of cell-tracking techniques, which have advanced our understanding of the fate and function of systemically infused MSC and might improve clinical application.
Details
- Title: Subtitle
- Mesenchymal stem cell therapy: Two steps forward, one step back
- Creators
- James Ankrum - Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Harvard Stem Cell Institute, Harvard-MIT Division of Health Sciences and Technology 65 Landsdowne Street, Cambridge, MA 02139, USAJeffrey M Karp
- Resource Type
- Journal article
- Publication Details
- Trends in molecular medicine, Vol.16(5), pp.203-209
- DOI
- 10.1016/j.molmed.2010.02.005
- PMID
- 20335067
- PMCID
- PMC2881950
- NLM abbreviation
- Trends Mol Med
- ISSN
- 1471-4914
- eISSN
- 1471-499X
- Publisher
- England
- Grant note
- R01 HL095722 / NHLBI NIH HHS DE019191 / NIDCR NIH HHS R03 DE019191-01A1 / NIDCR NIH HHS R03 DE019191 / NIDCR NIH HHS R01 GM086433 / NIGMS NIH HHS
- Language
- English
- Date published
- 05/2010
- Academic Unit
- Roy J. Carver Department of Biomedical Engineering
- Record Identifier
- 9984001157702771
Metrics
20 Record Views